Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
EWN Sport18d
Gilead licenses HIV-prevention drug to generic drugmakers
FILE: Gilead Sciences logo displayed on a laptop screen and medical pills are seen in this illustration photo taken in Krakow, Poland on 18 October 2021. Picture: Jakub Porzycki / NurPhoto ...
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...
Le Lézard11d
momencio unveils bold new brand and industry-leading features for event success
This transformation, marked by a fresh logo and modernized brand identity ... of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 Gilead Sciences, Inc. and Merck , known as ...
pharmaphorum9d
The B2C prescription: Marketing lessons for B2B pharma companies
That brand is more than just a logo - it’s your company’s reputation ... including a recent campaign from Gilead Science. Meanwhile, Kantar recorded a 208% jump in spending on podcast pharma ...
Gilead upgraded to outperform by Leerink on PrEP outlook
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Benzinga.com6h
Peering Into Gilead Sciences's Recent Short Interest
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...
Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Fintel on MSN3d
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform Recommendation
Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...